Introduction and application of CAS:668270-12-0 | Linagliptin
Uses Linagliptin, developed by Boehringer Ingelheim, was approved by the FDA on May 2, 2011. It is used to improve the control of blood sugar levels in patients with type 2 diabetes in combination with diet and exercise. Linagliptin improves glycemic control in patients by inhibiting dipeptidyl peptidase-4 (DPP-4).
Specification of CAS:668270-12-0 | Linagliptin
|
ITEMS |
SPECIFICATION |
|
CAS |
668270-12-0 |
| MF | C25H28N8O2 |
|
MW |
472.54 |
|
Melting point |
202 ºC |
|
Appearance |
White powder |
|
Purity |
99% |
|
Form |
Solid powder |
|
Storage condition |
2-8°C Keep in dark place |
| Production | China |
Package and transportation of CAS:668270-12-0 | Linagliptin
Package:1g,10g,50g,100g 1000g
Transportation: by courier/ by air/ by sea
Hot Tags: cas:668270-12-0 | linagliptin, China cas:668270-12-0 | linagliptin manufacturers, factory, Pharmaceutical Intermediates, Cordycepin, 2-Bromo-m-xylene, 3 deoxy adenosin, Methyl toluenesulfonate, Cellulose Acetate Butyrate
